Is ERIS Lifesciences Ltd debt-free?

No, ERIS Lifesciences Ltd is not debt-free with a debt-to-equity ratio of 0.89.

Home

ERIS Lifesciences Ltd

ERIS Lifesciences Ltd Financials

ERIS Lifesciences Ltd Financial Statement

ERIS Lifesciences Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Mar 2025	Dec 2024	Sep 2024
Revenue	421.52	407.52	442.37
Operating Expense	283.80	300.16	293.93
Net Profit	30.47	1.78	28.10
Net Profit Margin	7.23	0.44	6.35
Earning Per Share	2.24	0.13	2.06
EBIDTA	135.52	103.11	139.30
Effective Tax Rate	6.18	TBA	5.91

Particulars	Mar 2025
Revenue	421.52
Operating Expense	283.80
Net Profit	30.47
Net Profit Margin	7.23
Earning Per Share	2.24
EBIDTA	135.52
Effective Tax Rate	6.18

ERIS Lifesciences Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Total Revenue Annual	1,486.71	1,330.73	1,215.73
Operating Expenses Annual	1,032.89	825.61	731.74
Operating Profit Annual	488.64	522.38	512.98
Interest Annual	57.42	20.81	2.99
Depreciation	34.15	29.76	51.46
Net Profit Annual	299.71	398.01	417.19
Tax Annual	29.12	38.90	41.35

Particulars	Mar 2024
Total Revenue Annual	1,486.71
Operating Expenses Annual	1,032.89
Operating Profit Annual	488.64
Interest Annual	57.42
Depreciation	34.15
Net Profit Annual	299.71
Tax Annual	29.12

ERIS Lifesciences Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Cash Flow at the Beginning	47.48	44.70	31.35
Cash Flow from Operations	336.29	322.33	369.41
Cash Flow from Investing	-2,491.89	-513.30	-267.64
Cash Flow from Financing	2,160.06	193.75	-88.42
Cash Flow at the End	51.94	47.48	44.70

Particulars	Mar 2024
Cash Flow at the Beginning	47.48
Cash Flow from Operations	336.29
Cash Flow from Investing	-2,491.89
Cash Flow from Financing	2,160.06
Cash Flow at the End	51.94

ERIS Lifesciences Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
PBDIT Margin (%)	31.97	38.97	42.20
PBIT Margin (%)	25.27	34.15	37.97
PBT Margin (%)	24.83	32.51	25.52
Net PROFIT Margin (%)	19.61	29.69	34.32
Return On Networth / Equity (%)	12.63	19.23	23.88
Return On Networth /Employed (%)	9.98	19.94	25.68
Return On Assets (%)	7.65	17.22	23.33
Total Debt / Equity (X)	0.60	0.08	TBA
Asset Turnover Ratio (%)	0.39	0.58	0.68

Particulars	Mar 2024
PBDIT Margin (%)	31.97
PBIT Margin (%)	25.27
PBT Margin (%)	24.83
Net PROFIT Margin (%)	19.61
Return On Networth / Equity (%)	12.63
Return On Networth /Employed (%)	9.98
Return On Assets (%)	7.65
Total Debt / Equity (X)	0.60
Asset Turnover Ratio (%)	0.39

ERIS Lifesciences Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Fixed Assets Annual	1,516.17	898.16	644.99
Total Current Assets Annual	1,876.55	552.08	580.01
Non Current Assets Annual	3,473.02	2,231.58	1,570.41
Total Shareholders Funds Annual	2,524.02	2,221.88	1,918.56
Total Assets Annual	5,349.57	2,783.66	2,150.42

Particulars	Mar 2024
Fixed Assets Annual	1,516.17
Total Current Assets Annual	1,876.55
Non Current Assets Annual	3,473.02
Total Shareholders Funds Annual	2,524.02
Total Assets Annual	5,349.57

ERIS Lifesciences Ltd Earning Calls

EPS (INR)

Expected

6.89

Reported

6.90

Surprise

0.15%

Dec 2024

EPS beaten by 0.15%

Sep 2024

EPS beaten by 0.16%

Jun 2024

EPS beaten by 0.00%

Dividend Pages

PE Ratio

FAQS on ERIS Lifesciences Ltd Financials

As of Jun 6, 2025, ERIS Lifesciences Ltd has a market capitalization of 19,287.43 Cr. Value Research classifies it as a Large-Cap company.

Yes, ERIS Lifesciences Ltd is not with a debt-to-equity ratio of 0.89.

In FY 2024 , ERIS Lifesciences Ltd recorded a total revenue of approximately 1,663.63 Cr marking a significant milestone in the company's financial performance.

ERIS Lifesciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.5% and 0.1% annually, respectively..

ERIS Lifesciences Ltd's current PE ratio is 249.22.

ERIS Lifesciences Ltd's ROCE averaged 10.8% from the FY ending March 2023 to 2025, with a median of 7.6%. It peaked at 17.7% in March 2023, reflecting strong capital efficiency over the period..

ERIS Lifesciences Ltd's latest EBIT is Rs. 340.29 Cr, surpassing the average EBIT of Rs. 394.76 Cr over the 5 years..